Julie A. Johnson

4.4k total citations
9 papers, 305 citations indexed

About

Julie A. Johnson is a scholar working on Pharmacology, Pharmacology and Molecular Biology. According to data from OpenAlex, Julie A. Johnson has authored 9 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pharmacology, 3 papers in Pharmacology and 2 papers in Molecular Biology. Recurrent topics in Julie A. Johnson's work include Pharmacogenetics and Drug Metabolism (4 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Analytical Methods in Pharmaceuticals (2 papers). Julie A. Johnson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Analytical Methods in Pharmaceuticals (2 papers). Julie A. Johnson collaborates with scholars based in United States. Julie A. Johnson's co-authors include Vanessa L. Herring, Juanita J. Anders, Michael S. Wolfe, Mary V. Relling, Jay M. Sullivan, Michael S. Wolfe, Wendell S. Akers, Michael Pacanowski, Carl J. Pepine and Charles J. David and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Journal of Pharmaceutical Sciences and Glia.

In The Last Decade

Julie A. Johnson

9 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie A. Johnson United States 9 89 60 46 38 29 9 305
Hui C. Ko United States 5 67 0.8× 106 1.8× 41 0.9× 26 0.7× 27 0.9× 6 317
C H Gleiter Germany 8 83 0.9× 98 1.6× 49 1.1× 49 1.3× 26 0.9× 13 400
Lloyd Stevens United Kingdom 10 47 0.5× 74 1.2× 34 0.7× 27 0.7× 14 0.5× 16 323
Johan Wemer Netherlands 15 102 1.1× 103 1.7× 48 1.0× 44 1.2× 53 1.8× 34 460
J. K. Boeijinga Netherlands 8 125 1.4× 36 0.6× 57 1.2× 61 1.6× 42 1.4× 13 348
Monique Schmitt Switzerland 11 113 1.3× 109 1.8× 83 1.8× 61 1.6× 31 1.1× 23 607
Douglas S. Mautz United States 9 164 1.8× 50 0.8× 65 1.4× 50 1.3× 10 0.3× 20 359
Marie-Paule Gascon Switzerland 8 180 2.0× 69 1.1× 80 1.7× 67 1.8× 31 1.1× 9 448
S. Oliver United Kingdom 10 47 0.5× 30 0.5× 65 1.4× 35 0.9× 22 0.8× 20 313
Tillement Jp France 11 76 0.9× 118 2.0× 62 1.3× 41 1.1× 19 0.7× 72 381

Countries citing papers authored by Julie A. Johnson

Since Specialization
Citations

This map shows the geographic impact of Julie A. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie A. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie A. Johnson more than expected).

Fields of papers citing papers by Julie A. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie A. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie A. Johnson. The network helps show where Julie A. Johnson may publish in the future.

Co-authorship network of co-authors of Julie A. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Julie A. Johnson. A scholar is included among the top collaborators of Julie A. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie A. Johnson. Julie A. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Pacanowski, Michael, et al.. (2009). Genetic and Pharmacogenetic Associations Between NOS3 Polymorphisms, Blood Pressure, and Cardiovascular Events in Hypertension. American Journal of Hypertension. 22(7). 748–753. 16 indexed citations
2.
Johnson, Julie A.. (2001). Drug Target Pharmacogenomics. PubMed. 1(4). 271–281. 34 indexed citations
3.
Wang, Jianwei, Edward B. Mougey, Charles J. David, et al.. (2001). Determination of Human ??2-Adrenoceptor Haplotypes by Denaturation Selective Amplification and Subtractive Genotyping. PubMed. 1(4). 315–322. 11 indexed citations
4.
Johnson, Julie A., Vanessa L. Herring, Michael S. Wolfe, & Mary V. Relling. (2000). CYP1A2 and CYP2D6 4-Hydroxylate Propranolol and Both Reactions Exhibit Racial Differences. Journal of Pharmacology and Experimental Therapeutics. 294(3). 1099–1105. 46 indexed citations
5.
Johnson, Julie A., Wendell S. Akers, Vanessa L. Herring, Michael S. Wolfe, & Jay M. Sullivan. (2000). Gender Differences in Labetalol Kinetics: Importance of Determining Stereoisomer Kinetics for Racemic Drugs. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(6). 622–628. 26 indexed citations
6.
Parker, Robert B., et al.. (2000). Effects of COER‐Verapamil on Circadian Pattern of Forearm Vascular Resistance and Blood Pressure. The Journal of Clinical Pharmacology. 40(12). 1480–1487. 10 indexed citations
7.
Johnson, Julie A.. (1997). Influence of Race or Ethnicity on Pharmacokinetics of Drugs. Journal of Pharmaceutical Sciences. 86(12). 1328–1333. 111 indexed citations
8.
Herring, Vanessa L. & Julie A. Johnson. (1993). Direct high-performance liquid chromatographic determination in urine of the enantiomers of propranolol and its major basic metabolite 4-hydroxypropranolol. Journal of Chromatography B Biomedical Sciences and Applications. 612(2). 215–221. 25 indexed citations
9.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hui C. Ko Breakdown of academic impact, for papers by C H Gleiter Breakdown of academic impact, for papers by Lloyd Stevens Breakdown of academic impact, for papers by Johan Wemer Breakdown of academic impact, for papers by J. K. Boeijinga Breakdown of academic impact, for papers by Monique Schmitt Breakdown of academic impact, for papers by Douglas S. Mautz Breakdown of academic impact, for papers by Marie-Paule Gascon Breakdown of academic impact, for papers by S. Oliver Breakdown of academic impact, for papers by Tillement Jp
Rankless by CCL
2026